Cormedix Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on August 30, 2018. The filing addresses the status of the Company's listing on the NYSE American following a prior notice of non-compliance with continued listing standards.
Key Financial Metrics
The filing references historical financial data from the Company's Form 10-Q for the quarter ended March 31, 2018, which triggered the listing review:
- Stockholders' Equity: $0.8 million as of March 31, 2018.
- Profitability: The Company reported net losses in each of its five most recent fiscal years ended December 31, 2017.
- Revenue, Cash Flow, and Debt: The filing text does not provide specific values for revenue, operating cash flow, or debt levels.
Material Changes and Listing Status
On June 14, 2018, the NYSE American notified Cormedix that it failed to meet continued listing standards under Section 1003(a)(i), (ii), and (iii) of the Company Guide due to insufficient stockholders' equity relative to its history of net losses. Specifically, the Company failed to meet equity thresholds ranging from $2.0 million to $6.0 million depending on the duration of losses.
On August 30, 2018, the NYSE American accepted the Company's plan for continued listing. Consequently, the common stock will remain listed on the NYSE American, subject to quarterly reviews to ensure progress toward compliance.
Outlook, Risks, and Contingencies
The Company has until December 16, 2019, to regain full compliance with the applicable listing standards (the "Sections 1003(a)(i)-(iii) Plan Period").
- Delisting Risk: If the Company fails to comply with the standards within the specified timeframe or does not make progress consistent with its plan, the NYSE American will initiate delisting proceedings.
- Management Commentary: The filing confirms the submission of a compliance plan on July 16, 2018, and the subsequent acceptance of that plan by the exchange.
Investor Verification Checklist
- Verify the specific details of the compliance plan submitted on July 16, 2018, to understand the strategy for restoring stockholders' equity.
- Monitor upcoming quarterly reviews by NYSE Regulation to assess progress toward the December 16, 2019, compliance deadline.
- Review the attached press release (Exhibit 99.1) for additional context on the Company's financial position and operational strategy.
- Confirm whether the Company has reported any subsequent net losses or changes in equity in filings after March 31, 2018.